NASDAQ:PHIO Phio Pharmaceuticals (PHIO) Stock Price, News & Analysis $0.99 -0.01 (-1.49%) Closing price 10/2/2026 04:00 PM EasternExtended Trading$0.99 +0.01 (+0.70%) As of 10/2/2026 05:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC Filings About Phio Pharmaceuticals Stock (NASDAQ:PHIO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Phio Pharmaceuticals alerts:Sign Up Key Stats Today's Range$0.98▼$1.0250-Day Range$0.98▼$1.2152-Week Range$0.81▼$4.19Volume54,215 shsAverage Volume111,574 shsMarket Capitalization$11.44 millionP/E RatioN/ADividend YieldN/APrice Target$14.00Consensus RatingHold Company Overview Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company focused on developing immuno-oncology therapies. The company’s research centers on RNA interference (RNAi), a biological process that can reduce the production of specific proteins involved in disease. Phio is developing treatments intended to activate and enhance the body’s immune response against cancer. The company’s proprietary INTASYL™ platform is designed to deliver small interfering RNA (siRNA) directly into cells without requiring traditional delivery vehicles. Phio has used the platform to develop investigational compounds that target immune-regulating proteins. Its lead program, PH-762, is designed to inhibit PD-1 in immune cells and is being studied as a potential treatment for solid tumors and other cancers. The company has also advanced additional preclinical and clinical-stage programs, including compounds directed at other targets relevant to tumor immunity. Phio Pharmaceuticals was formerly known as RXi Pharmaceuticals and adopted its current name in 2018 to reflect its focus on the INTASYL platform and immuno-oncology. The company is headquartered in Marlborough, Massachusetts, and primarily conducts research and clinical development activities in the United States. Its products remain investigational and are not approved for commercial sale.AI Generated. May Contain Errors. Read More Phio Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks89th Percentile Overall ScorePHIO MarketRank™: Phio Pharmaceuticals scored higher than 89% of companies evaluated by MarketBeat, and ranked 43rd out of 887 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingHold Consensus RatingPhio Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.Upside PotentialPhio Pharmaceuticals has a consensus price target of $14.00, representing about 1,321.2% upside from its current price of $0.99.Amount of Analyst CoveragePhio Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.Read more about Phio Pharmaceuticals' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Phio Pharmaceuticals are expected to grow in the coming year, from ($1.45) to ($0.61) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Phio Pharmaceuticals is -0.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Phio Pharmaceuticals is -0.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPhio Pharmaceuticals has a P/B Ratio of 0.53. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Phio Pharmaceuticals' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.34% of the float of Phio Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverPhio Pharmaceuticals has a short interest ratio ("days to cover") of 0.96, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Phio Pharmaceuticals has recently decreased by 32.34%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPhio Pharmaceuticals does not currently pay a dividend.Dividend GrowthPhio Pharmaceuticals does not have a long track record of dividend growth. News and Social Media3.0 / 5News SentimentN/A News SentimentPhio Pharmaceuticals has a news sentiment score of 0.80. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.47 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 1 news article for Phio Pharmaceuticals this week, compared to 2 articles on an average week.MarketBeat Follows2 people have added Phio Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Company Ownership4.4 / 5Insider TradingAcquiring Shares Cluster Insider Buying3 insiders have purchased shares of Phio Pharmaceuticals in the last three months. Multiple insiders buying is a strong bullish signal.Net Insider BuyingOver the last three months, insiders have purchased a net $30,875.00 in company stock, which represents 0.2698% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Phio Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $30,875.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders3.52% of the stock of Phio Pharmaceuticals is held by insiders.Percentage Held by Institutions57.31% of the stock of Phio Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Phio Pharmaceuticals' insider trading history. Receive PHIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Phio Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PHIO Stock News HeadlinesPhio Announces Key PH-762 Milestone with FDA Submission for Next Stage of Cutaneous Squamous Cell CarcinomaSeptember 14, 2026 | markets.businessinsider.comPhio Announces Key Development Milestone for PH-762 with FDA Submission Supporting Next Stage of Clinical Development in Cutaneous Squamous Cell CarcinomaSeptember 14, 2026 | insidermonkey.comDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in could be a costly mistake. He calls it among the most overhyped, overvalued large-cap offerings ever pushed onto everyday investors. Tilson believes a rare economic event is approaching - one with serious consequences for your portfolio this summer. He has prepared a free analysis outlining what he sees and the specific steps he recommends taking now.October 3 at 1:00 AM | Stansberry Research (Ad)Phio Announces Key Development Milestone for PH-762 with FDA Submission Supporting Next Stage of Clinical Development in Cutaneous Squamous Cell CarcinomaSeptember 14, 2026 | finance.yahoo.comPhio Pharmaceuticals Corp.: Phio Pharmaceuticals Secures U.S. Notice of Allowance for INTASYL Composition Selectively Targeting BRD4 Protein with Compound PH-894August 12, 2026 | finanznachrichten.dePhio Pharmaceuticals Secures U.S. Notice of Allowance for INTASYL Composition Selectively Targeting BRD4 Protein with Compound PH-894August 12, 2026 | finance.yahoo.comPhio Pharmaceuticals expands global patent portfolio with new international patent milestonesJuly 15, 2026 | msn.comPhio Pharmaceuticals Announces "How siRNA Therapy can Change the Course of Cancer Treatment" in a Fireside Chat with Force Family Office on Monday, June 29, 2026June 25, 2026 | finance.yahoo.comSee More Headlines PHIO Stock Analysis - Frequently Asked Questions How have PHIO shares performed this year? Phio Pharmaceuticals' stock was trading at $1.05 on January 1st, 2026. Since then, PHIO shares have decreased by 6.2% and is now trading at $0.9851. How were Phio Pharmaceuticals' earnings last quarter? Phio Pharmaceuticals Corp. (NASDAQ:PHIO) posted its earnings results on Thursday, August, 6th. The company reported ($0.36) earnings per share for the quarter, hitting the consensus estimate of ($0.36). When did Phio Pharmaceuticals' stock split? Phio Pharmaceuticals's stock reverse split before market open on Friday, July 5th 2024.The 1-9 reverse split was announced on Friday, July 5th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, July 5th 2024. An investor that had 100 shares of stock prior to the reverse split would have 11 shares after the split. How do I buy shares of Phio Pharmaceuticals? Shares of PHIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Phio Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Phio Pharmaceuticals investors own include Zomedica (ZOM), Jumia Technologies (JMIA), Nano Dimension (NNDM), NIO (NIO), AST SpaceMobile (ASTS), Phunware (PHUN) and Virgin Galactic (SPCE). Company Calendar Last Earnings8/06/2026Today10/03/2026Next Earnings (Estimated)11/12/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (7m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 PHIO's financial health is in the Yellow zone, according to TradeSmith. PHIO has been in this zone for over 7 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:PHIO CIK1533040 Webphiopharma.com Phone(508) 767-3861Fax508-767-3862Employees6Year Founded2011Price Target and Rating Average Price Target for Phio Pharmaceuticals$14.00 High Price Target$14.00 Low Price Target$14.00 Potential Upside/Downside+1,321.2%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($1.29) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$8.70 million Net MarginsN/A Pretax MarginN/A Return on Equity-87.41% Return on Assets-79.76% Debt Debt-to-Equity RatioN/A Current Ratio8.39 Quick Ratio8.39 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.87 per share Price / Book0.53Miscellaneous Outstanding Shares11,617,000Free Float11,208,000Market Cap$11.44 million OptionableNot Optionable Beta0.84 Social Links 10 Best Stocks to Own in Fall 2026AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.Get This Free Report This page (NASDAQ:PHIO) was last updated on 10/3/2026 by MarketBeat.com Staff. From Our PartnersThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Phio Pharmaceuticals Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share Phio Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
